Cochrane · systematic review · CD012118
Drugs for treating Buruli ulcer (Mycobacterium ulcerans disease)
Yotsu, RR, Richardson, M, Ishii, N · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
2
current version
GRADE rated
2
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 50%Low 1 · 50%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Rifampicin combined with streptomycin compared with surgery alone for Buruli ulcer
Population: people with Buruli ulcer, non‐ulcerated lesions measuring less than 10 cm in diameter, aged 15 years or older
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Recurrence, 12 months Rifampicin combined with streptomycin vs surgery alone | RR 0.12 [0.01, 2.51] | 1 study · 21 participants | Very low Downgraded: risk of bias, imprecision |
Rifampicin with clarithromycin compared with rifampicin with streptomycin in the consolidation phase for Buruli ulcer
Population: people with Buruli ulcer, early lesions measuring less than 10 cm in diameter, aged 5 years or older
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Curea Rifampicin with clarithromycin vs rifampicin with streptomycin | RR 0.94 [0.87, 1.03] | 1 study · 151 participants | Low Downgraded: imprecision |